GLOWing reports on NVA237 at ERS show Novartis is set to challenge BI’s Spiriva
This article was originally published in Scrip
Novartis’ Phase III data for its inhaled long-acting muscarinic receptor antagonist (LAMA), NVA237 (glycopyrronium bromide;) presented at the European Respiratory Society (ERS) congress in Amsterdam, the Netherlands, shows substantial improvement in lung in patients with moderate-to-severe COPD. With the Swiss giant having filed for market authorisation in Europe (scripintelligence.com, 27 September 2011) and set for launch in 2012, observers expect a genuine challenge to the incumbent market leader, Boehringer Ingelheim’s Spiriva.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.